Hemostatic material, hemostatic means and material based thereon

FIELD: medicine.

SUBSTANCE: material comprising a hemostatic agent O,O'-dipalmitoyl chitosan or a salt thereof and one or more bioadhesive neutral substances are described.

EFFECT: increased hemostatic activity of modified chitosan, hydrophobically modified chitosan, high water solubility, increased hemostatic properties of the hemostatic material based on modified chitosan, expansion of the hemostatic arsenal.

28 cl, 7 tbl, 1 dwg, 11 ex

 



 

Same patents:

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine. What is described is a medical absorbable haemostatic and wound healing material for osteal wounds and a method for producing it. The absorbable haemostatic material for osteal wounds contains 40-95% of a primary material and 5-60% of an auxiliary on the basis of weight percentage, wherein the primary material contains an oligosaccharide, a polysaccharide or a mixture of the oligosaccharide and polysaccharide, while the auxiliary contains (1) one or more polyatomic alcohols, (2) one or more emulsifiers. The method for producing the absorbable haemostatic and wound healing material for osteal wounds consists of the following stages involving mixing the primary material and auxiliary in the pre-set amounts by chemical mixture and preparation of the mixture at the stage of latex, and cooling to form a solid piece, packaging and sterilising.

EFFECT: material is degradable in the body and promotes osteal wound healing.

7 cl, 4 tbl, 9 ex

FIELD: veterinary medicine.

SUBSTANCE: solution is administered intravenously to chinchilla male rabbits one hour prior to surgical interference. The solution is prepared as follows: sterile distilled water for injection is added to the lyophilised fibrin-monomer with urea, so that the resulting solution contains fibrin monomer at a concentration of 11 mg/ml and urea at a concentration of 150 mg/ml, and stirred until complete dissolution of the substance. At that the dose of fibrin-monomer is 0.25 mg/kg.

EFFECT: method is highly effective the prevention of bleeding caused by the use of streptokinase, prior to surgical interferences.

1 ex, 2 dwg

FIELD: veterinary medicine.

SUBSTANCE: solution is administered intravenously to chinchilla male rabbits one hour prior to surgical interference. The solution is prepared as follows: sterile distilled water for injections is added to lyophilised fibrin-monomer with urea, so that the resulting solution contains fibrin-monomer at a concentration of 11 mg/ml and the urea at a concentration of 150 mg/ml, and stirred until complete dissolution of the substance. The dose of fibrin-monomer is 0.25 mg/kg.

EFFECT: method is highly effective for prevention of bleeding caused by the use of dabigatran etexilate in the experiment.

2 dwg, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to medicine and deals with pharmaceutical composition, containing suspension, which includes mixture of hydrophobic medium and solid form, where solid form contains therapeutically effective quantity of octreotide and, at least, one salt of fatty acid with medium chain length, which has chain length from 6 to 14 carbon atoms, and matrix-forming polymer, selected from dextran and polyvinylpyrrolidone (PVP), with salt of fatty acid with medium chain length being present in composition in amount of 10% by weight or more. Group of inventions also deals with capsule, containing said composition, intended for peroral introduction; method of obtaining said pharmaceutical composition.

EFFECT: group of inventions relates to improvement of octreotide bioavailability.

100 cl, 39 ex, 10 dwg, 45 tbl

FIELD: medicine.

SUBSTANCE: medication based on tripeptide Ac-Ala-Phe-Lys-Pip·AcOH or its pharmaceutically acceptable salts is applied. The claimed medication can be made in the form of a solution, gel, plate or sponge.

EFFECT: application of the said medication makes it possible to considerably reduce the volume of haemorrhage and reduce the time of bleeding stopping due to high anti-plasmin activity of the tripeptide Ac-Ala-Phe-Lys-Pip·AcOH with the absence of side effects.

2 cl, 8 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: wound canal is packed with a preparation of recovered oxygenated cellulose. Thereafter in an entrance wound, the preparation is exposed to 2 cycles of cryotherapy with liquid nitrogen at a temperature of minus 196°C for 1-2 minutes until an ice crust is formed on the wound surface.

EFFECT: method provides excluding the possibility of bleeding and bile flowing from an inner surface of stab wounds, reducing a risk of recurrent bleedings, formation of liver haematomas postoperatively.

3 dwg, 2 tbl, 2 ex

Haemostatic agent // 2545991

FIELD: medicine.

SUBSTANCE: invention relates to medicine and veterinary and is intended for the acceleration of stopping bleeding in case of injury to blood vessels in traumas and wounds. A haemostatic agent contains 3-20 wt % of a polysaccharide, where the polysaccharide is represented by chitosan and/or starch, 0.1-2 wt % of calcium chloride and a 0.5-5% water solution of succinic or hydrochloric acid - the remaining part.

EFFECT: accelerating the initiation of the thrombus-forming process and enhancement of the regenerative ability of tissues in the area of wounds of different aetiology.

1 tbl, 14 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutically acceptable salts specified in a group consisting of sodium salt, lithium salt, potassium salt, calcium salt, magnesium salt, arginine salt, lysine salt, methanamine salt, dimethylamine salt, trimethylamine salt, ethylamine salt, diethylaminte salt, triethylamine salt, ethanolamine salt, piperazine salt, dibenzylethylene diamine salt, methyl glucamine salt, tromethamine salt, quaternary tetramethylammonium salt, quaternary tetraethylammonium salt and choline salt, bicyclosubstituted azopyrazole derivatives of general formula

.

The invention also refers to a method for preparing them, a pharmaceutical composition containing them, and using them as a therapeutic agent, particularly as thrombopoietin (TPO) mimetics, using them as TPO agonists. In general formula (I), Het is specified in a group consisting of phenyl, furanyl and thienyl; each R1, R2, R3 andR4 are independently specified in a group consisting of hydrogen and alkyl; n is equal to 0, 1 or 2.

EFFECT: improving the pharmokinetic properties of the compound of formula (I) ensured by better solubility.

19 cl, 1 tbl, 25 ex

FIELD: biotechnology.

SUBSTANCE: bispecific antibody is proposed, that binds to both the blood coagulation factor IX/activated blood coagulation factor IX and with the blood coagulation factor X, and functionally replaces the function of blood coagulation factor VIII. The nucleic acid is considered, encoding the antibody of the invention, a vector, a cell and a method of producing the antibody, and also a pharmaceutical composition and a kit for use in the method of preventing and/or treating bleeding or diseases associated with or caused by bleeding.

EFFECT: invention may find further application in the treatment of diseases associated with impaired blood clotting.

16 cl, 2 ex, 6 dwg

FIELD: chemistry.

SUBSTANCE: claimed is bispecific antibody, which is bound with both blood coagulation factor IX/activated blood coagulation factor IX and with blood coagulation factor X and functionally replaced function of blood coagulation factor VIII. Described are nucleic acid, coding antibody by invention, vector, cell and method of obtaining antibody, as well as pharmaceutical composition and set for application in method of prevention and/or treatment of bleeding or diseases, associated with or induced by bleeding.

EFFECT: invention can be applied in therapy of diseases, associated with blood coagulation disorders.

16 cl, 2 ex, 6 dwg

Crystals // 2556206

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention describes crystals of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulphonyl)acetamide ("compound A"), as a form I of the compound A crystal, which shows diffraction peaks at 9.4 degrees, 9.8 degrees, 17.2 degrees and 19.4 degrees in its power X-ray diffraction spectrum, as a form II of the compound A crystal, which shows diffraction peaks at 9.0 degrees, 12.9 degrees, 20.7 degrees and 22.6 degrees in its power X-ray diffraction spectrum, as a form III of the compound A crystal, which shows diffraction peaks at 9.3 degrees, 9.7 degrees, 16.8 degrees, 20.6 degrees and 23.5 degrees in its power X-ray diffraction spectrum. There are also described methods for producing the forms I, II and III of the compound A crystal, based pharmaceutical composition and PGI2 receptor agonist agent, an accelerating agent for angiogenic therapy, gene engineering or autoimmune bone marrow transplantation, and an accelerating agent for angiogenesis for peripheral artery recovery or angiogenic therapy on the basis thereof; there are also described a preventive or therapeutic agent for a wide range of diseases and conditions.

EFFECT: preparing the new therapeutic agent for the wide range of diseases and conditions.

11 cl, 6 dwg, 6 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: invention concerns using synthetic peptide of general formula H2N-L-Glu-L-Trp-D-Ala-COOH as a wound healing agent possessing the immunostimulatory effect.

EFFECT: creating the new synthetic wound healing agent having high biological activity.

2 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to oxazolopyramidine compounds of formula I, where A represents O; R1 is selected from phenyl or pyrimidine, which are optionally substituted with R11; R2 represents phenyl, which is optionally substituted wby 1-3 ring carbon atoms with similar or different substituents R22, R11 represents halogen; R22 is selected from hydroxy group, (C1-C4)-alkyl, which is optionallysubstituted with 1-3 atoms of fluorine, (C1-C4)-alkyloxy, (C1-C4)-alkyl-S(O)m-; m equals 2. Invention also relates to pharmaceutical composition, which contains formula I compounds, and to method of obtaining formula I compounds.

EFFECT: formula I compounds, intended for activation of EDG-1 receptor and applied for wound healing.

15 cl, 2 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to oxazolopyramidine compounds of formula (I), where A represents O; X represents (C1-C6)-alkanediyl or (C1-C6)-alkanediyloxy, where oxygen atom of (C1-C6)-alkanediyloxy is bound to group R2; Y represents pyrrolidinyl; R1 represents (C1-C4)-alkyl; R2 represents phenylene, optionally substituted by one or two carbon atoms in ring with similar or different substituent R22; R3 is selected from group, which consists of cycloalkyl-CuH2u-, where u equals 1; radical of saturated 3-10-member monocyclic ring, phenyl or pyridyl, where ring radical is optionally substituted by one or two carbon atoms of ring with substituent R31; R4 represents hydrogen; R22 represents (C1-C4)-alkyl; R31 is selected from group, which consists of halogen and (C1-C4)-alkyl. Invention also relates to (S)-l-[2-(2,6-dimethyl-4-{5-[methyl-(3,3,3-trifluoropropyl)amino]-7-propoxyoxazolo[5,4-d]pyrimidine-2-yl}phenoxy)acetyl]pyrrolidine-2-carboxylic acid, pharmaceutical composition and to method of obtaining compounds of formula (I) .

EFFECT: compounds of formula (I), intended for activation of EDG-1 receptor and applied for wound healing.

16 cl, 2 tbl, 2 ex

FIELD: veterinary medicine.

SUBSTANCE: wound is preliminary treated with antiseptics. Then the preparation is injected drug directly under the base of the lesion. The preparation is used as the extract from the reindeer velvet antlers at a dose of 5-10 ml per one wound three times, once every 5 days.

EFFECT: use of the preparation Pantoin, the extract of reindeer velvet antlers, enables to speed up significantly the healing process of tear-contused wounds in horses and facilitates significantly the process of wound healing, particularly in the pasture period of maintenance.

2 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: ointment contains wax 13-15 wt %, glycerol 15-20 % and vegetable oil; the prepared ointment mass is exposed to ozone for 15-20 min in a yield amount of 10 mg/l.

EFFECT: invention provides the advanced healing efficacy with no side effects by reducing the time of wound cleansing from purulo-necrotic tissues.

3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to combustiology, and can be applied in process of treating burn wounds of III a and III b degree. For this purpose applied are cultured dermal allofibroblasts on 5-8 passage with concentration 250000 cells/ml as part of composition, which includes as carrier hydroxyethylcellulose natrosol and native collagen. After uniform distribution of medication on wound surface relief fixing with inert mesh covering "Lomatul-N" is carried out.

EFFECT: invention makes it possible to achieve fast recovery skin, reduction of probability of burn disease complications, improvement of functional and cosmetic results of treatment.

1 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: burn-treating composition for local application based on Vaseline lanolin, or carbopol, or hydrogel; as an active substance, the composition contains 5% dry extract of the herbal raw material big-flowered self and self-heal containing 60% rosmarinic acid.

EFFECT: above composition is effective for treating burns; it is non-toxic.

7 tbl, 10 ex, 12 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to physiotherapy, dermatology and cosmetology, and can be used in stimulating regenerative processes in the face and/or neck skin. That is ensured by performing three stages, first two of which involve preparing to the third one. The first stage involves blood sampling from the patient, recovering the blood plasma, and enriching it with thrombocytes; the purified and enriched plasma is administered intradermally under the skin. Two days later, the second stage follows that involves the subcutaneous injections of hyaluronic acid. The third stage is performed 2-3 days later to expose different skin layers to laser light passing through different face and/or neck sections two to five times for one procedure. Passing once involves the alternating short-wave and long-wave laser exposure at a wave length of 1564-2940 nm. The procedure is repeated every 3-5 days with an increasing laser beam pulse energy from 35 mJ to 65 mJ.

EFFECT: method provides the safe effective stimulation of the regenerative processes in the face and/or neck skin ensured by the complex exposure covering different layers of derma and epidermis and involving different regeneration links.

2 ex

FIELD: medicine.

SUBSTANCE: invention represents an agent for treating septic wounds, pus pockets and trophic ulcers containing betaine hydrochloride, methyluracil, trimecaine, pepsin powder and polyethylene oxide 400 with the ingredients taken in certain proportions, wt %, and polyethylene oxide 400 is taken in an amount of 87.0-84.0 ml.

EFFECT: invention provides fastening necrolysis, intensifies bactericidal action, stimulates regeneration, prevents secondary infection.

4 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine. What is described is an absorbent product comprising an upper sheet, a lower sheet, an absorbent core between the upper sheet and the lower sheet, and a cyclodextrine complex containing cyclodextrine and at least three components bound to the cyclodextrine complex. The absorbent product has a total chromatographic peak area of the components released from the cyclodextrine complex into a closed space at the moment of time of 0 min is no more than approximately 0.50×108, a total chromatographic peak area of the components released from the cyclodextrine complex into the closed space at the moment of time of 30 min is at least approximately 1.00×108 and a total chromatographic peak area of the components released from the cyclodextrine complex into a closed space at the moment of time of 240 minutes is at least approximately 2.70×108.

EFFECT: absorbent product provides the effective release of the components of the cyclodextrine complex to reduce a body fluid odour.

10 cl, 4 dwg, 3 tbl, 3 ex

Up!